Science

Vivek Subbiah: Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing

Vivek Subbiah/LinkedIn

Apr 20, 2025, 09:19

Vivek Subbiah: Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared an article by Richard A. Furie, et al. on X:

“Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis:

Obinutuzumab = a humanized type II anti-CD20 monoclonal antibody approved in CLL.

A nice example of drug repurposing.”

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.

Authors: Richard A. Furie, et al.

Vivek Subbiah: Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing

Active Lupus Nephritis cancer CLL drug repurposing early-phase drug development fight against cancer Global fight against cancer Monoclonal Antibody Obinutuzumab OncoDaily Oncology Sarah Cannon Research Institute Vivek Subbiah

Hagop Kantarjian: Advances and Revolution in Adult ALL Therapy Over the Last Decade

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Top 10 Immunotherapy Fellowships and Grants to Watch in 2025

July Is Sarcoma Awareness Month: What You Need to Know

Pat Soon-Shiong: SARS-CoV-2 Infection Can Awaken Sleeping Cancer Cells